Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTOG 0529: A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal

X
Trial Profile

RTOG 0529: A Phase II Evaluation of Dose-Painted Intensity-Modulated Radiation Therapy (IMRT) in Combination With 5-Fluorouracil (5-FU) and Mitomycin-C for Reduction of Acute Morbidity in Carcinoma of the Anal Canal

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 13 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorouracil (Primary) ; Mitomycin (Primary)
  • Indications Anal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2022 Results from 2 prospective anal cancer trials(NRG/RTOG 0529 and NRG/RTOG 9811) evaluating whether more conformal radiation (using Intensity Modulated Radiation Therapy) results in improved toxicity as measured by the Toxicity Index published in the American Journal of Clinical Oncology
    • 05 Oct 2009 Additional lead trial investigator (Fanelle J) identified as reported by New Jersey Cancer Trial Connect.
    • 02 Jan 2008 Trial centre added.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top